European Union Cannabis Law

The European Union does not have a unified cannabis regulatory framework — cannabis law remains a member state competency. However, EU-level rules on food law (Novel Food Regulation), agricultural policy (hemp THC thresholds), pharmaceutical regulation (EMEA pathway), and internal market principles (free movement of goods) create a complex supranational overlay that affects every national cannabis regime within the bloc.

The European Court of Justice's 2020 Kanavape ruling (C-663/18) established that CBD derived from the whole cannabis plant is not a narcotic under EU law, fundamentally reshaping the European CBD market. EU pharmaceutical GMP standards (EU-GMP) are the gold standard for medical cannabis product supply chains operating across member states.

Bob Hoban has advised US operators and investors on the EU regulatory matrix, including Novel Food compliance for CBD products, EU-GMP certification strategy for medical cannabis producers, and the implications of EU single market law for cross-border cannabis commerce. Advisory areas include member state treaty obligations, EU agricultural subsidy programs for hemp, EMEA pathway analysis, and investment structuring for multi-market EU cannabis operations.